- Home
- BOLD vs KTTA Comparison
BOLD vs KTTA Comparison
Compare BOLD & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BOLD | KTTA |
|---|---|---|
| Founded | 2018 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.9M | 26.7M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BOLD | KTTA |
|---|---|---|
| Price | $1.28 | $0.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $4.00 | $3.00 |
| AVG Volume (30 Days) | 119.5K | ★ 484.4K |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $0.28 |
| 52 Week High | $2.77 | $3.85 |
Technical Indicators
Market Signals| Indicator | BOLD | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 61.70 | 42.74 |
| Support Level | $1.14 | $1.09 |
| Resistance Level | $1.24 | $1.30 |
| Average True Range (ATR) | 0.09 | 0.09 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 62.00 | 9.53 |
Price Performance
Historical ComparisonAbout BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).